Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2016

Open Access 01-07-2016 | Original Article

Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment

Authors: John Routes, Beatriz Tavares Costa-Carvalho, Bodo Grimbacher, Kenneth Paris, Hans D. Ochs, Alexandra Filipovich, Mary Hintermeyer, Karina Mescouto de Melo, Sarita Workman, Diane Ito, Xiaolan Ye, Patrick Bonnet, Josephine Li-McLeod

Published in: Journal of Clinical Immunology | Issue 5/2016

Login to get access

Abstract

Purpose

Health-related quality of life (HRQOL) has not been examined in patients with predominant antibody deficiency both pre- and post-immunoglobulin G (IgG) treatment initiation. HRQOL and health resource utilization (HRU) were assessed in newly diagnosed patients with primary immunodeficiency disease (PIDD) pre- and 12 months post-IgG treatment initiation.

Methods

Adults (age ≥18 years) completed the 36-item Short Form Health Survey, version 2; pediatric patients (PP)/caregivers completed the Pediatric Quality of Life Inventory (PedsQL). Scores were compared with normative data from the US general population (GP) and patients with other chronic conditions (OCC).

Results

Seventeen adult patients (APs), 8 PPs, and 8 caregivers completed baseline assessments. APs had significantly lower baseline mean physical component summary scores versus GP (37.4 vs 50.5, p < 0.01) adults with chronic back pain (44.1, p < 0.05) or cancer (44.4, p < 0.05) and lower mental component summary scores versus GP (41.6 vs 49.2, p < 0.05). PPs had lower PedsQL total (63.1 vs 82.7), physical summary (64.5 vs 84.5), and psychosocial summary (62.5 vs 81.7) scores versus GP. Post-IgG treatment, 14 APs, 6 PPs, and 8 caregivers completed assessments. Hospital admissions (0.2 versus 1.8, p < 0.01), serious infections (3.3 versus 10.9, p < 0.01) and antibiotic prescriptions (3.0 versus 7.1; p < 0.01) decreased significantly overall. While APs reported significant improvement in role-physical (p = 0.01), general health (p < 0.01), and social functioning (p = 0.02) and caregivers in vitality (p < 0.01), PPs did not.

Conclusions

Pre-IgG treatment, patients with PIDD experienced diminished HRQOL versus GP and patients with OCC; post-treatment, HRU decreased and certain HRQOL aspects improved for APs and caregivers.
Literature
1.
go back to reference Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726.
2.
go back to reference Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149:410–23.CrossRefPubMedPubMedCentral Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149:410–23.CrossRefPubMedPubMedCentral
3.
go back to reference Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131:314–23.CrossRefPubMed Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131:314–23.CrossRefPubMed
4.
go back to reference Cooper MA, Pommering TL, Korányi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed Cooper MA, Pommering TL, Korányi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed
5.
go back to reference Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109:581–91.CrossRefPubMed Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109:581–91.CrossRefPubMed
6.
go back to reference Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol. 2011;127:1414–7.CrossRefPubMed Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol. 2011;127:1414–7.CrossRefPubMed
10.
go back to reference Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.CrossRefPubMed Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.CrossRefPubMed
11.
go back to reference Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.CrossRefPubMed Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.CrossRefPubMed
12.
go back to reference Chapel HM, Spickett GP, Ericson D, Engl W, Eibl M, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.CrossRefPubMed Chapel HM, Spickett GP, Ericson D, Engl W, Eibl M, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.CrossRefPubMed
13.
go back to reference Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency disease. N Engl J Med. 1991;325:110–7.CrossRefPubMed Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency disease. N Engl J Med. 1991;325:110–7.CrossRefPubMed
14.
go back to reference Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.CrossRefPubMedPubMedCentral Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.CrossRefPubMedPubMedCentral
15.
go back to reference Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10 % liquid immune globulin preparation (GAMMAGARD LIQUID, 10 %) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323–31.CrossRefPubMed Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10 % liquid immune globulin preparation (GAMMAGARD LIQUID, 10 %) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323–31.CrossRefPubMed
16.
go back to reference Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7.CrossRefPubMed Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7.CrossRefPubMed
18.
go back to reference Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J. 2012;53:603–10.CrossRefPubMedPubMedCentral Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J. 2012;53:603–10.CrossRefPubMedPubMedCentral
19.
go back to reference Chan A, Scalchunes C, Boyle M, Puck JM. Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol. 2011;138:3–8.CrossRefPubMed Chan A, Scalchunes C, Boyle M, Puck JM. Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol. 2011;138:3–8.CrossRefPubMed
21.
go back to reference Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.CrossRefPubMed Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.CrossRefPubMed
22.
go back to reference Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126:81–8.CrossRefPubMed Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126:81–8.CrossRefPubMed
23.
go back to reference Winkelstein JA, Conley ME, James C, Howard V, Boyle J. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore). 2008;87:253–8.CrossRef Winkelstein JA, Conley ME, James C, Howard V, Boyle J. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore). 2008;87:253–8.CrossRef
24.
go back to reference Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allerty. 1991;67(5):504–10. Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allerty. 1991;67(5):504–10.
25.
go back to reference Ramírez-Vargas N, Arablin-Oropeza SE, Mojica-Martínez D, Yamazaki-Nakashimada MA, de la Luz G-CM, Terán-Juárez LM, et al. Clinical and immunological features of common variable immunodeficiency in Mexican patients. Allergol Immunopathol (Madr). 2014;42:235–40.CrossRef Ramírez-Vargas N, Arablin-Oropeza SE, Mojica-Martínez D, Yamazaki-Nakashimada MA, de la Luz G-CM, Terán-Juárez LM, et al. Clinical and immunological features of common variable immunodeficiency in Mexican patients. Allergol Immunopathol (Madr). 2014;42:235–40.CrossRef
26.
go back to reference Guaní-Guerra E, García-Ramírez UN, Jiménez-Romero AI, Velázquez-Ávalos JM, Gallardo-Martínez G, Mendoza-Espinoza FJ. Primary immunodeficiency diseases at reference and high-specialty hospitals in the state of Guanajuato, Mexico. Biomed Res Int. 2013;2013:187254.CrossRefPubMedPubMedCentral Guaní-Guerra E, García-Ramírez UN, Jiménez-Romero AI, Velázquez-Ávalos JM, Gallardo-Martínez G, Mendoza-Espinoza FJ. Primary immunodeficiency diseases at reference and high-specialty hospitals in the state of Guanajuato, Mexico. Biomed Res Int. 2013;2013:187254.CrossRefPubMedPubMedCentral
28.
go back to reference Jörgensen GH, Gardulf A, Sigurdsson MI, Arnlaugsson S, et al. Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL. Qual Life Res. 2014;23(2):645–58.CrossRefPubMed Jörgensen GH, Gardulf A, Sigurdsson MI, Arnlaugsson S, et al. Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL. Qual Life Res. 2014;23(2):645–58.CrossRefPubMed
29.
go back to reference Kuburovic NB, Pasic S, Susic G, Stevanovic D, et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323–30.CrossRefPubMedPubMedCentral Kuburovic NB, Pasic S, Susic G, Stevanovic D, et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323–30.CrossRefPubMedPubMedCentral
30.
go back to reference Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10(1):47–51.PubMed Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10(1):47–51.PubMed
31.
go back to reference Zebracki K, Palermo TM, Hostoffer R, Duff K, et al. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93(6):557–61.CrossRefPubMed Zebracki K, Palermo TM, Hostoffer R, Duff K, et al. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93(6):557–61.CrossRefPubMed
32.
go back to reference Soresina A, Nacinovich R, Bomba M, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29:501–7.CrossRefPubMed Soresina A, Nacinovich R, Bomba M, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29:501–7.CrossRefPubMed
33.
go back to reference Ware Jr JE, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Lincoln, RI: QualityMetric; 2000. Ware Jr JE, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Lincoln, RI: QualityMetric; 2000.
34.
go back to reference Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
35.
go back to reference McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMed McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMed
36.
go back to reference Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289–92.CrossRefPubMedPubMedCentral Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289–92.CrossRefPubMedPubMedCentral
37.
go back to reference Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.CrossRefPubMedPubMedCentral Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.CrossRefPubMedPubMedCentral
38.
go back to reference Varni JW, Burwinkle TM, Seid M. The PedsQL as a pediatric patient-reported outcome: reliability and validity of the PedsQL Measurement Model in 25,000 children. Expert Rev Pharmacoecon Outcomes Res. 2005;5:705–19.CrossRefPubMed Varni JW, Burwinkle TM, Seid M. The PedsQL as a pediatric patient-reported outcome: reliability and validity of the PedsQL Measurement Model in 25,000 children. Expert Rev Pharmacoecon Outcomes Res. 2005;5:705–19.CrossRefPubMed
39.
go back to reference Ware Jr JE, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1167–70.CrossRefPubMed Ware Jr JE, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1167–70.CrossRefPubMed
40.
go back to reference Maruish, ME (Ed.). User’s manual for the SF-36v2 health survey 3rd ed. Lincoln, RI: Quality Metric Incorporated. Maruish, ME (Ed.). User’s manual for the SF-36v2 health survey 3rd ed. Lincoln, RI: Quality Metric Incorporated.
41.
go back to reference Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001–2007. J Clin Immunol. 2014;34(8):954–61.CrossRefPubMedPubMedCentral Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001–2007. J Clin Immunol. 2014;34(8):954–61.CrossRefPubMedPubMedCentral
Metadata
Title
Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment
Authors
John Routes
Beatriz Tavares Costa-Carvalho
Bodo Grimbacher
Kenneth Paris
Hans D. Ochs
Alexandra Filipovich
Mary Hintermeyer
Karina Mescouto de Melo
Sarita Workman
Diane Ito
Xiaolan Ye
Patrick Bonnet
Josephine Li-McLeod
Publication date
01-07-2016
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2016
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0279-0

Other articles of this Issue 5/2016

Journal of Clinical Immunology 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.